Pipeline

Program Therapeutic Area/Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights
Internal Programs
Ralinepag
Potent IP Receptor Agonist
PAH – Time to Clinical Events

63%

PAH – Exercise Capacity (CPET)

63%

PAH – Exercise Capacity (6MW)

63%

PAH – Differentiation

58%

Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
Etrasimod
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) 1

63%

Ulcerative Colitis (UC) 2

63%

Crohn’s Disease (CD)

55%

Primary Biliary Cholangitis

55%

Arena: Worldwide, excluding rights granted to Everest Medicines for Greater China & certain other Asian territories
Olorinab
Highly Selective Full Agonist to CB2
Pain Associated with CD

55%

Arena: Worldwide
Partnered Programs
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Ongoing

98%

Eisai: Worldwide
Nelotanserin
5-HT2A Inverse Agonist
REM Sleep Behavior Disorder in Dementia with Lewy Bodies

41%

Axovant: Worldwide
Undisclosed Orphan GPCR
CNS

15%

Undisclosed Orphan GPCR
Undisclosed Novel GPCR
Genitourinary Disorders

15%

Outpost Medicine

Program Indication Phase
Internal Programs
Ralinepag
Potent IP Receptor Agonist
PAH – Time to Clinical Events Ph3
PAH – Exercise Capacity (CPET) Ph3
PAH – Exercise Capacity (6MW) Ph3
PAH – Differentiation Ph2
Etrasimod
Optimized Activity S1P Receptor Modulator
Ulcerative Colitis (UC) 1 Ph2
Ulcerative Colitis (UC) 2 Ph2
Crohn’s Disease (CD) Ph2
Primary Biliary Cholangitis Ph1
Olorinab
Highly Selective Full Agonist to CB2
Pain Associated with CD Ph2
Partnered Programs
BELVIQ and BELVIQ XR
Weight Loss Approved: CVOT Ongoing Post Market
Nelotanserin
5-HT2A Inverse Agonist
REM Sleep Behavior Disorder in Dementia with Lewy Bodies Ph2
Undisclosed Orphan GPCR
CNS PC
Undisclosed Novel GPCR
Genitourinary Disorders PC

Expanded Access Policy